This report - now in its third edition - analyses the sources and prices of medicines used to treat drug-resistant TB (DR-TB), examines the key factors that shape the access environment for DR-TB medicines, reviews the research and development landscape for DR-TB treatment regimens, and makes recommendations for the way forward to reach more people and improve treatment outcomes.
Msf Tb Report Utm3rdedition-2013
pdf — 3.82 MB